These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 6815503)

  • 41. [Evaluation of hemodynamic changes in patients with primary arterial hypertension after treatment with a combination of pindolol and clopamide (Viskaldix)].
    Wyrzykowski B; Suchecka-Rachoń K
    Kardiol Pol; 1991; 34(5):286-91. PubMed ID: 1921111
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Experience with Viskaldix].
    Jezersek P
    Lijec Vjesn; 1984; 106(11-12):518-20. PubMed ID: 6394940
    [No Abstract]   [Full Text] [Related]  

  • 43. [Treatment with Viskaldix in arterial hypertension].
    Datcu G; Datcu MD; Orhei M
    Rev Med Chir Soc Med Nat Iasi; 1987; 91(1):149-51. PubMed ID: 3659641
    [No Abstract]   [Full Text] [Related]  

  • 44. Long-term Viskaldix therapy in the treatment of hypertensive patients.
    Dudás M; Iványi J
    Ther Hung; 1985; 33(3):152-5. PubMed ID: 3842011
    [No Abstract]   [Full Text] [Related]  

  • 45. Antihypertensive therapy with guanfacine induces elevated plasma growth hormone levels in diabetic patients.
    Coves MJ; Gomis R; Casamitjana R; Lienas V; Vilaradell E
    J Med; 1989; 20(3-4):291-6. PubMed ID: 2572660
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Clinical trial of a new antihypertensive preparation: guanfacine].
    Rengo F; Ricciardelli B; Spirito G; Volpe M; Morrone G; Trimarco B; Condorelli M
    Boll Soc Ital Cardiol; 1979; 24(10):1097-102. PubMed ID: 400394
    [No Abstract]   [Full Text] [Related]  

  • 47. [Clinical pharmacology of the antihypertensive action of guanfacine].
    Safar M; Weiss Y; Georges D
    Arch Mal Coeur Vaiss; 1980 Oct; 73(10):1171-7. PubMed ID: 6778409
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Lifelong antihypertensive therapy.
    Klugman KP; Palmer J; Schultz E
    S Afr Med J; 1980 May; 57(21):851. PubMed ID: 6996131
    [No Abstract]   [Full Text] [Related]  

  • 49. [Antihypertensive therapy with guanfacine. A multicenter trial with Estulic Wander 1 mg].
    Schäfer N; Knaup G
    MMW Munch Med Wochenschr; 1982 Mar; 124(10):249-52. PubMed ID: 6806612
    [No Abstract]   [Full Text] [Related]  

  • 50. Comparative study of two antihypertensive agents: guanfacine and guanethidine.
    Szám I; Kállay K
    Br J Clin Pharmacol; 1980; 10 Suppl 1(Suppl 1):85S-87S. PubMed ID: 6994786
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Long-term antihypertensive therapy with guanfacine.
    Szám I; Holló J
    Int J Clin Pharmacol Ther Toxicol; 1982 Aug; 20(8):388-92. PubMed ID: 6749702
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Double-blind trial comparing guanfacine and methyldopa in patients with essential hypertension.
    Bune AJ; Chalmers JP; Graham JR; Howe PR; West MJ; Wing LM
    Eur J Clin Pharmacol; 1981; 19(5):309-15. PubMed ID: 7016550
    [No Abstract]   [Full Text] [Related]  

  • 53. [Effect of the combination of Pindolol and clopamide in systemic arterial hypertension. A multicenter study].
    Zilenovski AM; Freire CA
    Arq Bras Cardiol; 1981 Sep; 37(3):219-24. PubMed ID: 7052028
    [No Abstract]   [Full Text] [Related]  

  • 54. Improved exercise performance of hypertensive patients treated with guanfacine (Estulic Sandoz).
    Bazika V
    Cor Vasa; 1987; 29(4 Suppl 1):42-5. PubMed ID: 3315450
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Viskaldix for treatment of patients with moderate arterial hypertension. Comparative estimation of hemodynamic changes during treatment with Viskaldix and Stresson].
    Grajek S; Szymczyńska A; Urbański K; Lehman Z; Kozłowska F; Paradowski S; Gracz M
    Kardiol Pol; 1986; 29(7):440-53. PubMed ID: 2879953
    [No Abstract]   [Full Text] [Related]  

  • 56. Long-term clinical experience with guanfacine.
    Fetkovská N; Brimichová G; Sebeková K; Dzúrik R
    Cor Vasa; 1987; 29(4 Suppl 1):23-9. PubMed ID: 3315447
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prolactin, renin, growth hormone, lipoproteins and glucose under guanfacine treatment.
    Hauger-Klevene JH; Balossi EC; Scornavacchi JC
    Cor Vasa; 1987; 29(4 Suppl 1):17-22. PubMed ID: 3119290
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Long-term treatment of hypertension with guanfacine alone and in combination therapy.
    Seedat YK
    Br J Clin Pharmacol; 1980; 10 Suppl 1(Suppl 1):65S-66S. PubMed ID: 6994781
    [No Abstract]   [Full Text] [Related]  

  • 59. [Anti-hypertensive effectiveness of guanfacine and methyldopa: comparison of groups of patients].
    Malini PL; Strocchi E; Ambrosioni E; Magnani B
    Cardiologia; 1982; 27(4):357-63. PubMed ID: 6765262
    [No Abstract]   [Full Text] [Related]  

  • 60. Guanfacine in the treatment of hypertension: two years' experience with low dose monotherapy.
    Jerie P; Lasance A
    Int J Clin Pharmacol Ther Toxicol; 1981 Jun; 19(6):279-87. PubMed ID: 7030975
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.